This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Accuray (ARAY) Inks Cancer Treatment Technology Delivery Deal
by Zacks Equity Research
Accuray's (ARAY) new deal with DHL Supply Chain will help in the delivery of advanced cancer treatment technology.
Ecolab (ECL) Gets EPA Nod for Biofilm Disinfectant Virasept
by Zacks Equity Research
Ecolab's (ECL) Virasept has been developed to combat bacterial growth in hospitals.
Why Is Align Technology (ALGN) Down 2.6% Since Last Earnings Report?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEOGEN (NEOG), Transnetyx Partner to Advance Mouse Genotyping
by Zacks Equity Research
NEOGEN (NEOG) aims to better serve the biomedical research community with a comprehensive and affordable solution for the genetic background testing of their mouse models via the partnership.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
Here's Why You Should Avoid Betting on Integer Holdings (ITGR)
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational third-quarter 2020 performance weighs on Integer Holdings (ITGR).
QIAGEN (QGEN), BioNTech to Develop Test to Identify SCCHN
by Zacks Equity Research
QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.
NextGen (NXGN) Strengthens Portfolio of NextGen Solutions
by Zacks Equity Research
NextGen (NXGN) continues to boost its robust portfolio of NextGen solutions with the latest adoption of NextGen Enterprise by OSMC.
Allscripts' (MDRX) Veradigm Collaborates With HealthVerity
by Zacks Equity Research
Allscripts (MDRX) and HealthVerity will be committed toward catering to specific industry needs by helping clients design linked data solutions that are fit-for-purpose.
Hologic's (HOLX) Cervical Cancer Screening System Gets CE Mark
by Zacks Equity Research
Hologic (HOLX) becomes the provider of the first CE-Marked comprehensive cervical cancer screening portfolio with the new Genius Digital Diagnostics System.
Veeva Systems (VEEV) Boosts Portfolio of Cloud-Based Offerings
by Zacks Equity Research
Veeva Systems (VEEV) continues to boost its cloud-based offerings profile with the adoption of Vault PromoMats by Bristol Myers.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Medtronic's (MDT) Medicrea Buyout to Aid AI Spinal Surgery Line
by Zacks Equity Research
Medtronic (MDT) expects Medicrea's capabilities and solutions to complement its fully-integrated procedural solution for surgical planning and delivery.
QIAGEN (QGEN) Launches PCR Test, Expands Testing Portfolio
by Zacks Equity Research
QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.
Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows
by Zacks Equity Research
Teleflex (TFX) expects further adverse financial impact of the coronavirus pandemic.
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
by Zacks Equity Research
The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.
Here's Why You Should Invest in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
LHC Group (LHCG) Forays into Oklahoma With New Hospice Buyout
by Zacks Equity Research
LHC Group (LHCG) buys Grace Hospice of Oklahoma to expand its hospice service to Tulsa and throughout the nation.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALGN) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
PerkinElmer's Non-Invasive Saliva-Based Testing Gets CE Mark
by Zacks Equity Research
PerkinElmer's (PKI) new saliva-based collection and asymptomatic test solution receives CE-IVD mark.
Hologic (HOLX) Updates Its Unifi Platform, Enhances Portfolio
by Zacks Equity Research
Hologic (HOLX) introduces upgrades to its Unifi Analytics platform to help mammography centers improve their workflow.
Ecolab Introduces Exelerate TUFSOIL for Food Manufacturers
by Zacks Equity Research
Ecolab's (ECL) Exelerate TUFSOIL has been developed to increase production time and enhance cleaning outcomes to curb food safety risks and improve worker safety.